LRMR
Price:
$6.46
Market Cap:
$412.19M
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2014-06-19
Stock Exchange
NASDAQ
Ticker
LRMR
According to Larimar Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 382.49M. This represents a change of 12.45% compared to the average of 340.13M of the last 4 quarters.
The mean historical Enterprise Value of Larimar Therapeutics, Inc. over the last ten years is 197.68M. The current 382.49M Enterprise Value has changed 19.25% with respect to the historical average. Over the past ten years (40 quarters), LRMR's Enterprise Value was at its highest in in the March 2015 quarter at 1.12B. The Enterprise Value was at its lowest in in the December 2014 quarter at -50545000.00.
Average
197.68M
Median
126.33M
Minimum
58.04M
Maximum
843.61M
Discovering the peaks and valleys of Larimar Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 110.11%
Maximum Annual Enterprise Value = 843.61M
Minimum Annual Increase = -83.51%
Minimum Annual Enterprise Value = 58.04M
Year | Enterprise Value | Change |
---|---|---|
2023 | 178.55M | 110.11% |
2022 | 84.98M | -29.83% |
2021 | 121.11M | -37.18% |
2020 | 192.79M | 58.26% |
2019 | 121.81M | -6.90% |
2018 | 130.84M | 23.48% |
2017 | 105.96M | 82.56% |
2016 | 58.04M | -58.27% |
2015 | 139.09M | -83.51% |
The current Enterprise Value of Larimar Therapeutics, Inc. (LRMR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
128.21M
5-year avg
139.85M
10-year avg
197.68M
Larimar Therapeutics, Inc.’s Enterprise Value is less than Vaxcyte, Inc. (10.61B), less than Syndax Pharmaceuticals, Inc. (1.32B), less than Merus N.V. (2.63B), greater than Sutro Biopharma, Inc. (84.47M), greater than Immuneering Corporation (26.73M), less than Centessa Pharmaceuticals plc (2.15B), less than Celcuity Inc. (572.85M), greater than Ikena Oncology, Inc. (44.28M), greater than Spero Therapeutics, Inc. (-7881706.00), greater than Bolt Biotherapeutics, Inc. (31.17M), greater than Coherus BioSciences, Inc. (329.80M), less than Gracell Biotechnologies Inc. (5.63B), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Surrozen, Inc. (3.47M), less than Keros Therapeutics, Inc. (2.32B), greater than Kezar Life Sciences, Inc. (31.67M), greater than Cabaletta Bio, Inc. (5.67M), greater than Homology Medicines, Inc. (-103303255.00), less than Day One Biopharmaceuticals, Inc. (966.48M), greater than Alector, Inc. (209.01M),
Company | Enterprise Value | Market cap |
---|---|---|
10.61B | $11.63B | |
1.32B | $1.45B | |
2.63B | $3.06B | |
84.47M | $234.18M | |
26.73M | $67.69M | |
2.15B | $2.46B | |
572.85M | $488.25M | |
44.28M | $81.07M | |
-7881706.00 | $63.79M | |
31.17M | $22.36M | |
329.80M | $195.86M | |
5.63B | $989.87M | |
-6333315.00 | $8.20M | |
3.47M | $32.95M | |
2.32B | $2.84B | |
31.67M | $49.61M | |
5.67M | $161.05M | |
-103303255.00 | $3.02M | |
966.48M | $1.39B | |
209.01M | $211.53M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Larimar Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Larimar Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Larimar Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Larimar Therapeutics, Inc. (LRMR)?
What is the 3-year average Enterprise Value for Larimar Therapeutics, Inc. (LRMR)?
What is the 5-year average Enterprise Value for Larimar Therapeutics, Inc. (LRMR)?
How does the current Enterprise Value for Larimar Therapeutics, Inc. (LRMR) compare to its historical average?